Tempest Therapeutics, Inc. (TPST)
Market Cap | 47.10M |
Revenue (ttm) | n/a |
Net Income (ttm) | -29.76M |
Shares Out | 22.22M |
EPS (ttm) | -1.72 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 521,475 |
Open | 2.130 |
Previous Close | 2.140 |
Day's Range | 2.080 - 2.185 |
52-Week Range | 0.170 - 9.770 |
Beta | -2.64 |
Analysts | Strong Buy |
Price Target | 20.75 (+878.77%) |
Earnings Date | Aug 8, 2024 |
About TPST
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulate... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TPST stock is "Strong Buy." The 12-month stock price forecast is $20.75, which is an increase of 878.77% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/j/5/biotech7-2488210.jpg)
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Shares of Tempest Therapeutics Inc TPST are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
![](https://cdn.snapi.dev/images/v1/1/g/conf15-2485772.jpg)
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeuti...
![](https://cdn.snapi.dev/images/v1/2/p/press16-2467717.jpg)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeuti...
![](https://cdn.snapi.dev/images/v1/n/x/press19-2456990.jpg)
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' possible...
![](https://cdn.snapi.dev/images/v1/f/z/press20-2422765.jpg)
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutic...
![](https://cdn.snapi.dev/images/v1/y/7/press4-2362816.jpg)
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut...
![](https://cdn.snapi.dev/images/v1/v/0/press7-2356193.jpg)
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
BRISBANE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut...
![](https://cdn.snapi.dev/images/v1/2/r/press3-2331869.jpg)
Tempest Reports Year End 2023 Financial Results and Provides Business Update
BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut...
![](https://cdn.snapi.dev/images/v1/h/1/press7-2309661.jpg)
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut...
![](https://cdn.snapi.dev/images/v1/5/2/conf8-2165048.jpg)
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...
![](https://cdn.snapi.dev/images/v1/p/y/press3-2148442.jpg)
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...
![](https://cdn.snapi.dev/images/v1/w/0/im-802668size1777777777777778width800-2103216.jpg)
Tempest Therapeutics shares end wild week with 8% drop
Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.
![](https://cdn.snapi.dev/images/v1/d/z/im-848946size1777777777777778width800-2101302.jpg)
Tempest Therapeutics shares head back to earth after 4,000% gain
Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.
![](https://cdn.snapi.dev/images/v1/b/i/health-care-stocks-doctor-740x416-2101153.jpg)
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's ...
![](https://cdn.snapi.dev/images/v1/f/c/im-549568size1777777777777778width800-2099262.jpg)
Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise
Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with li...
![](https://cdn.snapi.dev/images/v1/4/y/press13-2098494.jpg)
Tempest Adopts Limited Duration Stockholder Rights Plan
BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...
![](https://cdn.snapi.dev/images/v1/c/r/press7-2098485.jpg)
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and ...
![](https://cdn.snapi.dev/images/v1/l/9/conf3-2097656.jpg)
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET
![](https://cdn.snapi.dev/images/v1/c/o/press5-2068896.jpg)
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and...
![](https://cdn.snapi.dev/images/v1/5/1/press16-2018407.jpg)
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...
![](https://cdn.snapi.dev/images/v1/b/u/conf10-1915191.jpg)
Tempest to Present at the Jefferies Global Healthcare Conference
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i...
![](https://cdn.snapi.dev/images/v1/w/w/conf3-1908600.jpg)
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety profile ...
![](https://cdn.snapi.dev/images/v1/s/n/press11-1899884.jpg)
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i...
![](https://cdn.snapi.dev/images/v1/l/b/press8-1883549.jpg)
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and i...
![](https://cdn.snapi.dev/images/v1/x/d/conf12-1859523.jpg)
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...